$ARCT News

Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27

Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

Arcturus Therapeutics Q1 Earnings Call Highlights

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Holdings Appoints Dennis Mulroy As CFO Effective May 1, 2026

Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf

B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22

Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing

Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews

Citigroup Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $21

Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary

Citigroup Maintains Neutral on Arcturus Therapeutics, Raises Price Target to $8